These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 28600754)
61. Frequency, predictors, and outcomes of urine drug testing among patients with advanced cancer on chronic opioid therapy at an outpatient supportive care clinic. Arthur JA; Edwards T; Lu Z; Reddy S; Hui D; Wu J; Liu D; Williams JL; Bruera E Cancer; 2016 Dec; 122(23):3732-3739. PubMed ID: 27509305 [TBL] [Abstract][Full Text] [Related]
62. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse. McCarberg BH Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462 [TBL] [Abstract][Full Text] [Related]
63. Development of an Algorithm to Identify Cannabis Urine Drug Test Results within a Multi-Site Electronic Health Record System. Morasco BJ; Shull SE; Adams MH; Dobscha SK; Lovejoy TI J Med Syst; 2018 Jul; 42(9):163. PubMed ID: 30043122 [TBL] [Abstract][Full Text] [Related]
64. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence. Accurso AJ; Rastegar DA J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639 [TBL] [Abstract][Full Text] [Related]
65. Relationship of Opioid Prescriptions to Physical Therapy Referral and Participation for Medicaid Patients with New-Onset Low Back Pain. Thackeray A; Hess R; Dorius J; Brodke D; Fritz J J Am Board Fam Med; 2017; 30(6):784-794. PubMed ID: 29180553 [TBL] [Abstract][Full Text] [Related]
66. Clinical monitoring and high-risk conditions among patients with SUD newly prescribed opioids and benzodiazepines. Grossbard JR; Malte CA; Saxon AJ; Hawkins EJ Drug Alcohol Depend; 2014 Sep; 142():24-32. PubMed ID: 24969956 [TBL] [Abstract][Full Text] [Related]
67. Which patients receive an addiction consult? A preliminary analysis of the INREACH (INpatient REadmission post-Addiction Consult Help) study. D'Amico MJ; Walley AY; Cheng DM; Forman LS; Regan D; Yurkovic A; Samet JH; Weinstein ZM J Subst Abuse Treat; 2019 Nov; 106():35-42. PubMed ID: 31540609 [TBL] [Abstract][Full Text] [Related]
68. Validity of the DSM-5 craving criterion for alcohol, tobacco, cannabis, cocaine, heroin, and non-prescription use of prescription painkillers (opioids). Shmulewitz D; Stohl M; Greenstein E; Roncone S; Walsh C; Aharonovich E; Wall MM; Hasin DS Psychol Med; 2023 Apr; 53(5):1955-1969. PubMed ID: 35506791 [TBL] [Abstract][Full Text] [Related]
69. Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Koyyalagunta D; Bruera E; Engle MP; Driver L; Dong W; Demaree C; Novy DM Pain Med; 2018 Jul; 19(7):1469-1477. PubMed ID: 29016951 [TBL] [Abstract][Full Text] [Related]
70. Analysis of Urine Drug Test Results From Substance Use Disorder Treatment Practices and Overdose Mortality Rates, 2013-2020. Whitley P; LaRue L; Fernandez SA; Passik SD; Dawson E; Jackson RD JAMA Netw Open; 2022 Jun; 5(6):e2215425. PubMed ID: 35657623 [TBL] [Abstract][Full Text] [Related]
71. A national study of clinical discussions about cannabis use among Veteran patients prescribed opioids. Zaman T; Bravata DM; Byers A; Krebs E; Leonard S; Austin C; Sandbrink F; Hasin DS; Keyhani S J Cannabis Res; 2024 Mar; 6(1):12. PubMed ID: 38493111 [TBL] [Abstract][Full Text] [Related]
72. Opioid dose risk, clinician and patient characteristics, and adherence to opioid prescribing recommendations in chronic non-cancer pain. Coleman C; Lennon RP; Robinson JM; Tuan WJ; Sehgal N; Zgierska AE J Opioid Manag; 2023; 19(5):413-422. PubMed ID: 37968975 [TBL] [Abstract][Full Text] [Related]
73. Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder. Lin LA; Powell VD; Macleod C; Bohnert ASB; Lagisetty P J Subst Abuse Treat; 2022 Oct; 141():108827. PubMed ID: 35863212 [TBL] [Abstract][Full Text] [Related]
74. Reasons for Opioid Discontinuation and Unintended Consequences Following Opioid Discontinuation Within the TOPCARE Trial. Husain JM; LaRochelle M; Keosaian J; Xuan Z; Lasser KE; Liebschutz JM Pain Med; 2019 Jul; 20(7):1330-1337. PubMed ID: 29955866 [TBL] [Abstract][Full Text] [Related]
75. Long-term opioid therapy of non-cancer pain : Prevalence and predictors of hospitalization in the event of possible misuse. Häuser W; Schubert T; Scherbaum N; Tölle T Schmerz; 2020 May; 34(Suppl 1):8-15. PubMed ID: 30327867 [TBL] [Abstract][Full Text] [Related]
76. Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Dong H; Hayashi K; Milloy MJ; DeBeck K; Singer J; Wong H; Wood E; Kerr T Drug Alcohol Depend; 2020 Jul; 212():108005. PubMed ID: 32370932 [TBL] [Abstract][Full Text] [Related]
77. Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial. Liebschutz JM; Xuan Z; Shanahan CW; LaRochelle M; Keosaian J; Beers D; Guara G; O'Connor K; Alford DP; Parker V; Weiss RD; Samet JH; Crosson J; Cushman PA; Lasser KE JAMA Intern Med; 2017 Sep; 177(9):1265-1272. PubMed ID: 28715535 [TBL] [Abstract][Full Text] [Related]
78. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017 [TBL] [Abstract][Full Text] [Related]